{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kao YT"],"funding":["National Science and Technology Council","Linkou Chang Gung Memorial Hospital"],"pagination":["1485"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11440110"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(9)"],"pubmed_abstract":["<h4>Background</h4>Hepatocellular carcinoma (HCC) remains a significant concern for patients with chronic hepatitis C (HCV), even after achieving a sustained virological response (SVR) with direct-acting antivirals (DAAs) or interferon (IFN)-based therapies. This study compared the risk of HCC in patients with HCV who achieved SVR through the DAA versus IFN regimens.<h4>Methods</h4>A retrospective analysis was conducted on 4806 HCV patients, without coinfection nor prior HCC history, treated at the Chang Gung Memorial Hospital, Taiwan (DAA: 2825, IFN: 1981). Kaplan-Meier and Cox regression analyses with propensity score matching (PSM) were used to adjust for baseline differences.<h4>Results</h4>DAA-treated patients exhibited a higher incidence of HCC than IFN-treated patients before and af"],"journal":["Viruses"],"pubmed_title":["Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents."],"pmcid":["PMC11440110"],"funding_grant_id":["CMRPG3N0851","NMRPG3P6021"],"pubmed_authors":["Tai JC","Hsieh YC","Kao YT","Chen YC","Wen YW","Chien RN","Cheng YT","Lin CY","Su CW","Sheen IS","Tai DI","Jeng WJ","Liu YC","Hsu CE"],"additional_accession":[]},"is_claimable":false,"name":"Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.","description":"<h4>Background</h4>Hepatocellular carcinoma (HCC) remains a significant concern for patients with chronic hepatitis C (HCV), even after achieving a sustained virological response (SVR) with direct-acting antivirals (DAAs) or interferon (IFN)-based therapies. This study compared the risk of HCC in patients with HCV who achieved SVR through the DAA versus IFN regimens.<h4>Methods</h4>A retrospective analysis was conducted on 4806 HCV patients, without coinfection nor prior HCC history, treated at the Chang Gung Memorial Hospital, Taiwan (DAA: 2825, IFN: 1981). Kaplan-Meier and Cox regression analyses with propensity score matching (PSM) were used to adjust for baseline differences.<h4>Results</h4>DAA-treated patients exhibited a higher incidence of HCC than IFN-treated patients before and af","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2025-04-04T02:20:01.564Z","creation":"2025-04-04T02:20:01.564Z"},"accession":"S-EPMC11440110","cross_references":{"pubmed":["39339961"],"doi":["10.3390/v16091485"]}}